| [1] |
Balmant NV, de Souza Reis R, Pinto Oliveira JF, et al. Cancer incidence among adolescents and young adults (15 to 29 years) in Brazil [J]. J Pediatr Hematol Oncol,2016,38(3):88-96.
|
| [2] |
Lee RC, Feinbaum RL. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J].Cell,1993,75(5):843-854.
|
| [3] |
Piva R, Spandidos DA. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (review) [J]. Int J Oncol,2013,43(4):985-994.
|
| [4] |
Li Y, Di C, Li W, et al. Erratum to: oncomirs miRNA-221/222 and tumor suppressors miRNA199a/-195 are crucial miRNAs in liver cancer: a systematic analysis [J]. Dig Dis Sci,2016,61(11):3373.
|
| [5] |
Cho WC. Exploiting the therapeutic potential of microRNAs in human cancer[J]. Expert Opin Ther Targets,2012,16(4):345-350.
|
| [6] |
Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 [J]. J Biol Chem, 2007, 282(32):23 716-23 724.
|
| [7] |
Dentelli P, Traversa M, Rosso A, et al. miR-221/222 control luminal breast cancer tumor progression by regulating different targets [J]. Cell Cycle,2014,13(11):1811-1826.
|
| [8] |
Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer [J]. J Biol Chem,2016,291:22 859.
|
| [9] |
Slattery ML, Lundgreen A, Kadlubar SA, et al. JAK/STAT/SOCSsignaling pathway and colon and rectal cancer [J]. Mol Carcinog,2013,52(2):155-166.
|
| [10] |
Li Y,Liang C,Ma H,et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer [ J].Molecules,2014,19:7122-7137.
|
| [11] |
le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1)tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation[J]. EMBO J,2007,26(15):3699-3708.
|
| [12] |
Visone R,Russo L,Pallante P,et al. MicroRNA -221 (miR-221) and miR-222, both overexpressed in human thyroid papillary carcinomas,regulate p27Kip1 protein levels and cell cycle [J]. Endocr Relat Cancer,2007,14(3):791-798.
|
| [13] |
Lu Y, Roy S, Nuovo G, et al. Anti-microRNA-222 (anti-miR-222)and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal [J]. J Biol Chem,2011,286(49):42292-42302
|
| [14] |
Wang H, Xu C, Kong X, et al. Trail resistance induces epithelial mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer [J]. PLoS One,2014,9(6):99 067.
|
| [15] |
Stinson S,Lackner MR,Adai AT,et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer[J]. Sci Signal,2011,4(177):ra41.
|
| [16] |
Ye X,Bai W,Zhu H,et al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN[J].BMB Rep,2014,47(5):268-273.
|
| [17] |
Dentelli P, Traversa M, Rosso A, et al. miR-221/222 control luminal breast cancer tumor progression by regulating different targets [J]. Cell Cycle,2014,13(11):1811-1826.
|
| [18] |
Yao Y, Chen S, Zhou X, et al. 5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells [J]. Oncol Lett,2014,7(2):541-547.
|
| [19] |
Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells [J].Breast Cancer Res Treat,2014,147(2):423-431.
|
| [20] |
Gan R, Yang Y, Yang X, et al. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3 [J]. Cancer Gene Ther, 2014, 21 (7):290-296.
|
| [21] |
Knutson TP, Truong TH, Ma S, et al. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs[J]. J Hematol Oncol, 2017,10(1):89.
|
| [22] |
Ke J, Zhao Z, Hong SH, et al. Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells[J]. Oncotarget,2015,6(6):3709-3721.
|
| [23] |
Ginestier C,Hur MH,Charafe-Jauffret E,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell,2007,1(5):555-567.
|
| [24] |
Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer[J]. Clin Cancer Res,2010,16(1):45-55.
|
| [25] |
Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer [J]. Int J Mol Sci,2016,17(3):421.
|
| [26] |
Li B, Lu Y, Wang H, et al. miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway[J]. Biomed Pharmacother,2016,79:93-101.
|
| [27] |
Roscigno G, Quintavalle C, Donnarumma E, et al. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b [J]. Oncotarget,2016,7(1):580-592.
|